Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01247493 | Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)(m-FLAI) | completed | Phase 2 | 108 | Seoul National University HospitalOTHER | 1 | Nov 24, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 |
| Oct 22, 2010 |
| clinicaltrials |
| NCT01220544 | Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells | unknown | Phase 1 / Phase 2 | 30 | Charite University, Berlin, GermanyOTHER | 1 | Oct 14, 2010 | clinicaltrials |
| NCT01133886 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure(DEC-MDS) | unknown | Phase 2 | 50 | King's College LondonOTHER | 1 | Sep 3, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT01146977 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)(CBF(+)AML) | unknown | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 22, 2010 | clinicaltrials |
| NCT00048503 | Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older | completed | Phase 2 | 88 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 27, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT01063660 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 75 | medac GmbHINDUSTRY | 1 | Feb 5, 2010 | clinicaltrials |
| NCT01039363 | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Dec 25, 2009 | clinicaltrials |
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | completed | Phase 2 | 200 | University Hospital MuensterOTHER | 1 | Aug 19, 2009 | clinicaltrials |
| NCT00510939 | Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia(HEMOS AML 0106) | unknown | Phase 2 | 72 | University of BolognaOTHER | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00391014 | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis(AMBINEB) | completed | Phase 2 | 150 | PETHEMA FoundationOTHER | 1 | May 12, 2009 | clinicaltrials |
| NCT00866073 | Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | completed | Phase 2 | 238 | University Hospital FreiburgOTHER | 2 | Mar 20, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00707408 | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 15 | Nantes University HospitalOTHER | 1 | Feb 2, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00116467 | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | completed | Phase 2 | 55 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00273884 | Amonafide in Combination With Cytarabine in Secondary AML | completed | Phase 2 | 80 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 19, 2007 | clinicaltrials |
| NCT00329498 | L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | suspended | Phase 2 | 25 | Samsung Medical CenterOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00044733 | Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant | completed | Phase 2 | 38 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | May 18, 2006 | clinicaltrials |
| NCT00153582 | WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 25 | Charite University, Berlin, GermanyOTHER | 1 | Feb 22, 2006 | clinicaltrials |
| NCT00209833 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | unknown | Phase 2 / Phase 3 | 200 | Hannover Medical SchoolOTHER | 1 | Nov 18, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2010source: clinicaltrials